News

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Shares of Hims & Hers, which has clashed with Novo Nordisk over its sales of compounded glucagon-like peptide inhibitors, rose slightly in the wake of the report, and have more than doubled in value ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
storage.googleapis.com on MSN18h
Novo Just Lost $100B and Blamed HIMS
Novo Nordisk ($NVO) lost nearly $100 billion in market cap in one session and pointed fingers at Hims & Hers Health ($HIMS) as the reason. Shay calls out the absurdity of a $300B company blaming a ...
Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...
Faire, the leading global wholesale platform powering independent retail, today announced the appointment of Christopher Payne, former President and Chief Operating Officer of DoorDash, to its Board ...
In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.
July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...
Novo Nordisk falls as company slashes 2025 forecasts as US sales of Wegovy and Ozempic face headwinds from compounded drugs.
Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, ...